Pioneer Hi Bred International issued US patent for 'soybean variety XB44E12'
Nevin Barich
ALEXANDRIA, Virginia
,
April 8, 2014
(U.S. Fed News)
–
United States Patent no. 8,692,077, issued on April 8, was assigned to Pioneer Hi-Bred International Inc (Johnston, Iowa).
"Soybean variety XB44E12" was invented by Les Charles Kuhlman (Lawrence, Kan.), Thomas C. Corbin (Monticello, Ill.), Leon G. Streit (Johnston, Iowa) and Jeffrey A. Thompson (Edwardsville, Ill.).
According to the abstract* released by the U.S. Patent & Trademark Office: "A novel soybean variety, designated XB44E12 is provided. Also provided are the seeds of soybean variety XB44E12, cells from soybean variety XB44E12, plants of soybean XB44E12, and plant parts of soybean variety XB44E12. Methods provided include producing a soybean plant by crossing soybean variety XB44E12 with another soybean plant, methods for introgressing a transgenic trait, a mutant trait, and/or a native trait into soybean variety XB44E12, methods for producing other soybean varieties or plant parts derived from soybean variety XB44E12, and methods of characterizing soybean variety XB44E12. Soybean seed, cells, plants, germplasm, breeding lines, varieties, and plant parts produced by these methods and/or derived from soybean variety XB44E12 are further provided."
The patent was filed on March 1, 2012, under Application No. 13/409,192.
*For further information, including images, charts and tables, please visit: http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=1&f=G&l=50&co1=AND&d=PTXT&s1=8692077&OS=8692077&RS=8692077
For any query with respect to this article or any other content requirement, please contact Editor at htsyndication@hindustantimes.com
(c) 2014 US Fed News (HT Syndication)
* All content is copyrighted by Industry Intelligence, or the original respective author or source. You may not recirculate, redistrubte or publish the analysis and presentation included in the service without Industry Intelligence's prior written consent. Please review our terms of use.